Compare Inovio Pharmaceuticals Inc (INO) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.93. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | JNK | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Fixed Income |
52-Week High | $2.87 | $98.19 |
52-Week Low | $1.05 | $94.66 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
JNK trades at $95.95, down slightly by 0.03% with a bearish technical outlook from moving averages and oscillators. The ETF shows consistent dividend payments but lacks key financial ratio data for fundamental assessment. Recent news highlights bond market volatility and investor focus on high-yield opportunities amid Federal Reserve uncertainty.
The outlook remains cautious due to technical weakness and macroeconomic pressures from potential rate hikes. Risks include fee erosion over time and sensitivity to interest rate changes, while the current yield may appeal to income-focused investors in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
